

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C07H 21/04, C12N 15/00, 1/20, C07K 14/435, 16/00, C12P 21/02, G01N 33/566, 33/53, C12Q 1/68</b>		<b>A2</b>	(11) International Publication Number: <b>WO 99/54343</b>
			(43) International Publication Date: <b>28 October 1999 (28.10.99)</b>
(21) International Application Number: <b>PCT/US99/08896</b>		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>23 April 1999 (23.04.99)</b>		Published <i>With declaration under Article 17(2)(a); without abstract; title not checked by the International Searching Authority.</i>	
(30) Priority Data: <b>09/065,661 23 April 1998 (23.04.98) US</b>			
(71) Applicant: <b>MILLENNIUM BIOTHERAPEUTICS, INC. [US/US]; 620 Memorial Drive, Cambridge, MA 02142 (US).</b>			
(72) Inventor: <b>HOLTZMAN, Douglas; 821 Centre Street #6, Jamaica Plain, MA 02130 (US).</b>			
(74) Agent: <b>MEIKLEJOHN, Anita, L.; Fish &amp; Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).</b>			

(54) Title: NOVEL MOLECULES OF THE T139-RELATED PROTEIN FAMILY AND USES THEREOF

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

NOVEL MOLECULES OF THE T139-RELATED PROTEIN  
FAMILY AND USES THEREOF

5 Background of the Invention

The invention relates to a novel secreted protein and the gene encoding it.

Many membrane-associated and secreted proteins, for example, cytokines, play a vital role in the 10 regulation of cell growth, cell differentiation, and a variety of specific cellular responses. A number of medically useful proteins, including erythropoietin, granulocyte-macrophage colony stimulating factor, human growth hormone, and various interleukins, are secreted 15 proteins. Thus, an important goal in the design and development of new therapies is the identification and characterization of membrane-associated and secreted proteins and the genes which encode them.

Many membrane-associated proteins are receptors 20 which bind a ligand and transduce an intracellular signal, leading to a variety of cellular responses. The identification and characterization of such a receptor enables one to identify both the ligands which bind to the receptor and the intracellular molecules and signal 25 transduction pathways associated with the receptor, permitting one to identify or design modulators of receptor activity, e.g., receptor agonists or antagonists and modulators of signal transduction.

Summary of the Invention

30 The present invention is based, at least in part, on the discovery of a gene encoding T139. The T139 cDNA described below (SEQ ID NO:1) has a 1338 nucleotide open reading frame (nucleotides 95-1432 of SEQ ID NO:1; SEQ ID NO:3) which encodes a 446 amino acid protein (SEQ ID 35 NO:2). This protein includes a predicted signal sequence

- 2 -

of about 26 amino acids (from about amino acid 1 to about amino acid 26 of SEQ ID NO:2) and a predicted mature protein of about 420 amino acids (from about amino acid 27 to amino acid 446 of SEQ ID NO:2; SEQ ID NO:4). T139 5 protein possesses a sperm-coating protein (SCP) domain (amino acids 47 to 190, of SEQ ID NO:2; SEQ ID NO:5), a C-type lectin domain (amino acids 297 to 412, of SEQ ID NO:2; SEQ ID NO:6), and two epidermal growth factor (EGF)-like domains (amino acids 232 to 260 of SEQ ID 10 NO:2; SEQ ID NO:7, referred to herein as the "EGF1 domain" and amino acids 264 to 291 of SEQ ID NO:2; SEQ ID NO:8, referred to herein as the "EGF2 domain").

The T139 molecules of the present invention are useful as modulating agents in regulating a variety of 15 cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding T139 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of 20 T139-encoding nucleic acids.

The invention features a nucleic acid molecule which is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the 25 cDNA insert of the plasmid deposited with ATCC as Accession Number (the "cDNA of ATCC 98694"), or a complement thereof. The invention features a nucleic acid molecule which includes a fragment of at least 300 (325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 30 800, 900, 1000, or 1290) nucleotides of the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA of ATCC 98694, or a complement thereof.

The invention also features a nucleic acid 35 molecule which includes a nucleotide sequence encoding a

- 3 -

protein having an amino acid sequence that is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or the amino acid sequence encoded by the cDNA of ATCC 98694.

5 In a preferred embodiment, a T139 nucleic acid molecule has the nucleotide sequence shown SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA of ATCC 98694.

Also within the invention is a nucleic acid 10 molecule which encodes a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, the fragment including at least 15 (25, 30, 50, 100, 150, 300, or 400) contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4 or the polypeptide encoded by the cDNA of ATCC 15 98694.

The invention includes a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by 20 the cDNA of ATCC 98694, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions.

Also within the invention are: an isolated T139 protein having an amino acid sequence that is at least 25 about 65%, preferably 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:4 (mature human T139) or the amino acid sequence of SEQ ID NO:2 (immature human T139); and an isolated T139 protein having an amino acid sequence that is at least about 85%, 95%, or 98% 30 identical to the SCP-like domain of SEQ ID NO:2 (e.g., about amino acid residues 47 to 190 of SEQ ID NO:2), C-type lectin domain (e.g., about amino acid residues 297 to 412 of SEQ ID NO:2), and EGF-like domains (e.g., about amino acids residues 232 to 260 or 264 to 291 of SEQ ID 35 NO:2).

Also within the invention are: an isolated T139 protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 65%, preferably 75%, 85%, or 95% identical to SEQ ID NO:3 or the cDNA of ATCC 98694; an isolated T139 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical to the SCP-like domain encoding portion of SEQ ID NO:1 (e.g., about nucleotides 233 to 665 of SEQ ID NO:1), or EGF-like domain encoding portion of SEQ ID NO:1 (e.g., about nucleotides 983 to 1330 of SEQ ID NO:1); and an isolated T139 protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence to a nucleic acid molecule of SEQ ID NO:3 or the non-coding strand of the cDNA of ATCC 98694.

Also within the invention is a polypeptide which includes the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA of ATCC 98694, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions.

Another embodiment of the invention features T139 nucleic acid molecules which specifically detect T139 nucleic acid molecules. For example, in one embodiment, conditions to a nucleic acid molecule hybridizes under stringent nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694, or a complement thereof. In another embodiment, the T139 nucleic acid molecule is at least

- 5 -

300 (325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, or 1290) nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ 5 ID NO:1, SEQ ID NO:3, the cDNA of ATCC 98694, or a complement thereof. In a preferred embodiment, an isolated T139 nucleic acid molecule comprises nucleotides 233 to 665 of SEQ ID NO:1, encoding the SCP-like domain of T139; nucleotides 983 to 1330 of SEQ ID NO:1, encoding 10 the C-type lectin domain of T139; or nucleotides 788 to 874 or 884 to 967 of SEQ ID NO:1, encoding a EGF like domain of T139, or a complement thereof. In another embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of 15 a T139 nucleic acid.

Another aspect of the invention provides a vector, e.g., a recombinant expression vector, comprising a T139 nucleic acid molecule of the invention. In another embodiment the invention provides a host cell containing 20 such a vector. The invention also provides a method for producing T139 protein by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector such that a T139 protein is produced.

25 Another aspect of this invention features isolated or recombinant T139 proteins and polypeptides. Preferred T139 proteins and polypeptides possess at least one biological activity possessed by naturally occurring human T139, e.g., (1) the ability to form protein:protein 30 interactions with proteins; and (2) the ability to bind a T139 ligand. Other activities include: (1) modulation of cellular proliferation and (2) modulation of cellular differentiation.

The T139 proteins of the present invention, or 35 biologically active portions thereof, can be operatively

- 6 -

linked to a non-T139 polypeptide (e.g., heterologous amino acid sequences) to form T139 fusion proteins. The invention further features antibodies that specifically bind T139 proteins, such as monoclonal or polyclonal 5 antibodies. In addition, the T139 proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

In another aspect, the present invention provides 10 a method for detecting the presence of T139 activity or expression in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of T139 activity such that the presence of T139 activity is detected in the biological sample.

15 In another aspect, the invention provides a method for modulating T139 activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) T139 activity or expression such that T139 activity or expression in the cell is modulated. In one embodiment, 20 the agent is an antibody that specifically binds to T139 protein. In another embodiment, the agent modulates expression of T139 by modulating transcription of a T139 gene, splicing of a T139 mRNA, or translation of a T139 mRNA. In yet another embodiment, the agent is a nucleic 25 acid molecule having a nucleotide sequence that is antisense to the coding strand of the T139 mRNA or the T139 gene.

In one embodiment, the methods of the present invention are used to treat a subject having a disorder 30 characterized by aberrant T139 expression or activity by administering an agent which is a T139 modulator to the subject. In one embodiment, the T139 modulator is a T139 protein. In another embodiment the T139 modulator is a T139 nucleic acid molecule. In other embodiments, the 35 T139 modulator is a peptide, peptidomimetic, or other

- 7 -

small molecule. In a preferred embodiment, the disorder characterized by aberrant T139 protein or nucleic acid expression is a proliferative or differentiative disorder, particularly of the immune system.

5 T139 nucleic acids, polypeptides, and modulators of T139 expression or activity can be used to modulate spermatogenesis. For example, such molecules can be used as a contraceptive to decrease spermatogenesis. Alternatively, such molecules can be used to increase  
10 spermatogenesis. Such molecules may also be useful for treatment of disorders related to defects in sperm-egg fusion and disorders of acrosome formation or function. T139 nucleic acids, polypeptides, and modulators may also be useful for treatment of various testicular disorders,  
15 e.g., testicular cancer. T139 may serve as an antigen in a contraceptive vaccinogen.

The present invention also provides a diagnostic assay for identifying the presence or absence of a genetic lesion or mutation characterized by at least one  
20 of: (i) aberrant modification or mutation of a gene encoding a T139 protein; (ii) mis-regulation of a gene encoding a T139 protein; and (iii) aberrant post-translational modification of a T139 protein, wherein a wild-type form of the gene encodes a protein with a T139  
25 activity.

In another aspect, the invention provides a method for identifying a compound that binds to or modulates the activity of a T139 protein. In general, such methods entail measuring a biological activity of a  
30 T139 protein in the presence and absence of a test compound and identifying those compounds which alter the activity of the T139 protein.

The invention also features methods for identifying a compound which modulates the expression of

- 8 -

T139 by measuring the expression of T139 in the presence and absence of a compound.

Other features and advantages of the invention will be apparent from the following detailed description 5 and claims.

Brief Description of the Drawings

Figure 1 depicts the cDNA sequence (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of human T139 (also referred to as "TANGO 139"). The open reading 10 frame of SEQ ID NO:1 extends from nucleotide 95 to nucleotide 1432 (SEQ ID NO:3).

Figures 2A-2C depict alignments of portions the amino acid sequences of T139 with various consensus sequences. Figure 2A shows the alignment of T139 amino 15 acids 47 to 190 of SEQ ID NO:2 with the SCP-like domain consensus sequence derived from a hidden Markov model (PF00188; SEQ ID NO:9). Figure 2B shows the alignment of T139 amino acids 297 to 412 of SEQ ID NO:2 with the C-type lectin domain consensus sequence derived from a 20 hidden Markov model (PF00059; SEQ ID NO:10). Figure 2C shows the alignment of T139 amino acids 232 to 260 (EGF1) and 264 to 291 (EGF2) of SEQ ID NO:2 with the EGF-like domain consensus sequence derived from a hidden Markov model (PF00008; SEQ ID NO:11).

25 Figure 3 is a hydropathy plot of T139. The position of cysteines (cys) are indicated by the vertical bars immediately below the plot. Relative hydrophobicity is shown above the dotted line, and relative hydrophilicity is shown below the line.

30

Detailed Description of the Invention

The present invention is based on the discovery of a cDNA molecule encoding human T139.

A nucleotide sequence encoding a human T139 protein is shown in Figure 1 (SEQ ID NO:1; SEQ ID NO:3

- 9 -

includes the open reading frame only). A predicted amino acid sequence of T139 protein is also shown in Figure 1 (SEQ ID NO: 2).

The T139 cDNA of Figure 1 (SEQ ID NO:1), which is approximately 1856 nucleotides long, including untranslated regions, encodes a protein amino acid having a molecular weight of approximately 49 kDa (excluding post-translational modifications). A plasmid containing a cDNA encoding human T139 was deposited with American Type Culture Collection (ATCC), Rockville, Maryland on March 12, 1998, and assigned Accession Number 98694. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

Sequence analysis revealed that T139 is homologous to testis-specific protein-1 (TPX-1), a member of the SCP-like domain protein family. Comparison of the T139 SCP-like domain with the SCP-like domain consensus (SEQ ID NO:9) revealed that the T139 SCP-like domain is 28% identical (45/162 amino acids) and 50% similar (81/162 amino acids) to the consensus.

Alignment of the C-type lectin domain of human T139 protein (SEQ ID NO:6) with the C-type lectin domain consensus sequence (SEQ ID NO:10) revealed that the domains are 27% identical (28/103 amino acids) and 63% similar (65/103 amino acids). C-type lectin domains appear to function as calcium-dependent carbohydrate-recognition domains and contain four conserved cysteines. The first and fourth cysteines and the second and third cysteines in the consensus participate in disulfide bonding with each other. One example of a protein having a C-type lectin domain is the REG protein, a 166 amino

- 10 -

acid polypeptide shown to stimulate beta-cell regeneration in a adult mouse pancreas. For a review on the REG protein, see Baeza et al. (1996) *Diab. Metab.* 22:229-234.

5 Alignment of the EGF-like domains of human T139 protein (SEQ ID NOS:7 and 8) with the EGF-like domain consensus sequence (SEQ ID NO:11) revealed that the EGF1 domain is 38% identical (13/34 amino acids) and 71% similar (24/34 amino acids). In general, EGF-like 10 domains are found in the extracellular portion of membrane-bound proteins or in secreted proteins. EGF-like domains typically include six cysteine residues involved in disulfide bond formation with two conserved glycines between the fifth and sixth cysteine. The 15 secondary structure of EGF-like domains appears to be a two-stranded  $\beta$ -sheet followed by a loop to a C-terminal short two-stranded sheet.

Tango 139 is expressed at high levels in the kidney and at low levels in the testis as an about 2.0 kb 20 transcript. Additional T139 transcripts of about 2.4 kb and 3.5 kb were also present in these two tissues. No T139 expression was observed in the heart, brain, placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, ovaries, small intestine, colon, and peripheral 25 blood leukocytes.

Human T139 is one member of a family of molecules (the "T139 family") having certain conserved structural and functional features. The term "family" when referring to the protein and nucleic acid molecules of 30 the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence identity as defined herein. Such family members can be naturally occurring and can be from either the same or 35 different species. For example, a family can contain a

- 11 -

first protein of human origin and a homologue of that protein of murine origin, as well as a second, distinct protein of human origin and a murine homologue of that protein. Members of a family may also have common

5 functional characteristics.

In one embodiment, a T139 protein includes a SCP-like, C-type lectin, or EGF-like domain having at least about 65%, preferably at least about 75%, and more preferably about 85%, 95%, or 98% amino acid sequence 10 identity to the SCP-like domain of SEQ ID NO:5, C-type lectin domain of SEQ ID NO:6, or EGF-like domain of SEQ ID NOS:7 or 8.

Preferred T139 polypeptides of the present invention have an amino acid sequence sufficiently 15 identical to the SCP-like domain of SEQ ID NO:5, C-type lectin domain of SEQ ID NO:6, or EGF-like domain of SEQ ID NOS:7 or 8. As used herein, the term "sufficiently identical" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of 20 identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common 25 functional activity. For example, amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.

30 As used interchangeably herein a "T139 activity", "biological activity of T139" or "functional activity of T139", refers to an activity exerted by a T139 protein, polypeptide or nucleic acid molecule on a T139 responsive cell as determined *in vivo*, or *in vitro*, according to 35 standard techniques. A T139 activity can be a direct

- 12 -

activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular signaling activity mediated by interaction of the T139 protein with a second protein.

5 In a preferred embodiment, a T139 activity includes at least one or more of the following activities: (i) interaction with other proteins; and (ii) interaction with a T139 receptor.

Accordingly, another embodiment of the invention 10 features isolated T139 proteins and polypeptides having a T139 activity.

Yet another embodiment of the invention features T139 molecules which contain a signal sequence.

Generally, a signal sequence (or signal peptide) is a 15 peptide containing about 20 amino acids which occurs at the extreme N-terminal end of secretory and integral membrane proteins and which contains large numbers of hydrophobic amino acid residues and serves to direct a protein containing such a sequence to a lipid bilayer.

20 Various aspects of the invention are described in further detail in the following subsections.

### I. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode T139 proteins or 25 biologically active portions thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify T139-encoding nucleic acids (e.g., T139 mRNA) and fragments for use as PCR primers for the amplification or mutation of T139 nucleic acid molecules. 30 As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The

- 13 -

nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are 5 present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic 10 DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated T139 nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic 15 acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or 20 substantially free of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 25 98694, or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of 30 ATCC 98694 as a hybridization probe, T139 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., *Molecular Cloning: A Laboratory Manual*. 2nd, ed., *Cold Spring Harbor Laboratory*, Cold Spring Harbor 35 Laboratory Press, Cold Spring Harbor, NY, 1989).

- 14 -

A nucleic acid of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so 5 amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to T139 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

10 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694, or a portion thereof. A nucleic 15 acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

20 Moreover, the nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding T139, for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of T139. The nucleotide 25 sequence determined from the cloning of the human T139 gene allows for the generation of probes and primers designed for use in identifying and/or cloning T139 homologues in other cell types, e.g., from other tissues, as well as T139 homologues from other mammals. The 30 probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 75, 100, 125, 150, 35 175, 200, 250, 300, 350 or 400 consecutive nucleotides of

- 15 -

the sense or anti-sense sequence of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694 or of a naturally occurring mutant of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694.

5 Probes based on the human T139 nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or identical proteins. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an 10 enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which mis-express a T139 protein, such as by measuring a level of a T139-encoding nucleic acid in a sample of cells from a subject, e.g., detecting T139 mRNA levels or 15 determining whether a genomic T139 gene has been mutated or deleted.

A nucleic acid fragment encoding a "biologically active portion of T139" can be prepared by isolating a portion of SEQ ID NO:1, SEQ ID NO:3, or the nucleotide 20 sequence of the cDNA of ATCC 98694 which encodes a polypeptide having a T139 biological activity, expressing the encoded portion of T139 protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of T139. For example, a nucleic acid 25 fragment encoding a biologically active portion of T139 includes a SCP-like, C-type lectin, or EGF-like domain, e.g., any of SEQ ID NOS:5-8.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ 30 ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694 due to degeneracy of the genetic code and thus encode the same T139 protein as that encoded by the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694.

- 16 -

In addition to the human T139 nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in 5 the amino acid sequences of T139 may exist within a population (e.g., the human population). Such genetic polymorphism in the T139 gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" 10 refer to nucleic acid molecules comprising an open reading frame encoding a T139 protein, preferably a mammalian T139 protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the T139 gene. Any and all such nucleotide 15 variations and resulting amino acid polymorphisms in T139 that are the result of natural allelic variation and that do not alter the functional activity of T139 are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding T139 20 proteins from other species (T139 homologues), which have a nucleotide sequence which differs from that of a human T139, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the T139 cDNA 25 of the invention can be isolated based on their identity to the human T139 nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a 30 membrane-bound human T139 cDNA can be isolated based on its identity to soluble T139.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 300 (325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 35 800, 900, 1000, or 1290) nucleotides in length and

- 17 -

hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694.

5 As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to  
10 each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in  
15 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, SEQ ID NO:3,  
20 the cDNA of ATCC 98694 corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

25 In addition to naturally-occurring allelic variants of the T139 sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, the cDNA  
30 of ATCC 98694, thereby leading to changes in the amino acid sequence of the encoded T139 protein, without altering the functional ability of the T139 protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid  
35 residues. A "non-essential" amino acid residue is a

- 18 -

residue that can be altered from the wild-type sequence of T139 (e.g., the sequence of SEQ ID NO:2) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.

5 For example, amino acid residues that are conserved among the T139 proteins of various species are predicted to be particularly unamenable to alteration.

For example, preferred T139 proteins of the present invention, contain at least one SCP-like, C-type 10 lectin, or EGF-like domain. Such conserved domains are less likely to be amenable to mutation. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved among T139 of various species) may not be essential for activity and thus are likely to be 15 amenable to alteration.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding T139 proteins that contain changes in amino acid residues that are not essential for activity. Such T139 proteins differ in 20 amino acid sequence from SEQ ID NO:2 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45% identical, 65%, 75%, 85%, 95%, 25 or 98% identical to the amino acid sequence of SEQ ID NO:2.

An isolated nucleic acid molecule encoding a T139 protein having a sequence which differs from that of SEQ ID NO:2 can be created by introducing one or more 30 nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, the cDNA of ATCC 98694 such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by 35 standard techniques, such as site-directed mutagenesis

- 19 -

and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which 5 the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, 10 histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, 15 methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in T139 is preferably replaced with another amino acid residue 20 from the same side chain family. Alternatively, mutations can be introduced randomly along all or part of a T139 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for T139 biological activity to identify mutants that 25 retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

In a preferred embodiment, a mutant T139 protein can be assayed for: (1) the ability to form 30 protein:protein interactions with proteins; or (2) the ability to bind a T139 receptor. In yet another preferred embodiment, a mutant T139 can be assayed for the ability to modulate cellular proliferation or cellular differentiation.

- 20 -

The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire T139 coding strand, or to only a portion thereof, e.g., all or 5 part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to a noncoding region of the coding strand of a nucleotide sequence encoding T139. The noncoding regions ("5' and 3' untranslated regions") are the 5' and 3' 10 sequences which flank the coding region and are not 15 translated into amino acids.

Given the coding strand sequences encoding T139 disclosed herein (e.g., SEQ ID NO:1 or SEQ ID NO:3), antisense nucleic acids of the invention can be designed 20 according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of T139 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of T139 25 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of T139 mRNA, e.g., an oligonucleotide having the sequence CTCTGGATGCAGCATGGGTCTGTTGGGCC (SEQ ID NO:12) or GATGCAGCATGGGTCTGTTG (SEQ ID NO:13). An 30 antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. 35 For example, an antisense nucleic acid (e.g., an

- 21 -

antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical 5 stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5- 10 fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- 15 galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2- 20 thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4- 25 thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using 30 an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

- 22 -

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a T139 5 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which 10 binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid 15 molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by 20 linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the 25 antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

An antisense nucleic acid molecule of the 30 invention can be an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier et al. (1987) *Nucleic Acids. Res.* 35 15:6625-6641). The antisense nucleic acid molecule can

- 23 -

also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) *FEBS Lett.* 215:327-330).

5 The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead 10 ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave T139 mRNA transcripts to thereby inhibit translation of T139 mRNA. A ribozyme having specificity for a T139-encoding nucleic acid can be designed based upon the 15 nucleotide sequence of a T139 cDNA disclosed herein (e.g., SEQ ID NO:1, SEQ ID NO:3). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence 20 to be cleaved in a T139-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742. Alternatively, T139 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, 25 e.g., Bartel and Szostak (1993) *Science* 261:1411-1418.

The invention also encompasses nucleic acid molecules which form triple helical structures. For example, T139 gene expression can be inhibited by targeting nucleotide sequences complementary to the 30 regulatory region of the T139 (e.g., the T139 promoter and/or enhancers) to form triple helical structures that prevent transcription of the T139 gene in target cells. See generally, Helene (1991) *Anticancer Drug Des.* 6(6):569-84; Helene (1992) *Ann. N.Y. Acad. Sci.* 660:27-35 36; and Maher (1992) *Bioassays* 14(12):807-15.

In preferred embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the 5 molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) *Bioorganic & Medicinal Chemistry* 4 (1):5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic 10 acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under 15 conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670-675.

20 PNAs of T139 can be used therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting 25 replication. PNAs of T139 can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as 'artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996) *supra*; or as 30 probes or primers for DNA sequence and hybridization (Hyrup (1996) *supra*; Perry-O'Keefe et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14670-675).

In another embodiment, PNAs of T139 can be modified, e.g., to enhance their stability or cellular 35 uptake, by attaching lipophilic or other helper groups to

PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of T139 can be generated which may combine the advantageous properties 5 of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths 10 selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup, (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) *supra* and Finn et al. (1996) *Nucleic Acids Research* 24(17):3357-63. For 15 example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA 20 (Mag et al. (1989) *Nucleic Acid Res.* 17:5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) *Nucleic Acids Research* 24(17):3357-63). Alternatively, chimeric molecules can 25 be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser et al. (1975) *Bioorganic Med. Chem. Lett.* 5:1119-1124).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for 30 targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or 35 the blood-brain barrier (see, e.g., PCT Publication No.

- 26 -

W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al. (1988) *Bio/Techniques* 6:958-976) or intercalating agents (see, e.g., Zon (1988) *Pharm. 5 Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

### II. Isolated T139 Proteins and Anti-T139 Antibodies

10 One aspect of the invention pertains to isolated T139 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-T139 antibodies. In one embodiment, native T139 proteins can be isolated from 15 cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, T139 proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a T139 protein or polypeptide can be 20 synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from 25 the cell or tissue source from which the T139 protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of T139 protein in which the 30 protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, T139 protein that is substantially free of cellular material includes preparations of T139 protein having less than about 30%, 20%, 10%, or 5% (by

- 27 -

dry weight) of non-T139 protein (also referred to herein as a "contaminating protein"). When the T139 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When T139 protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of T139 protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or non-T139 chemicals.

Biologically active portions of a T139 protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the T139 protein (e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:4), which include less amino acids than the full length T139 proteins, and exhibit at least one activity of a T139 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the T139 protein. A biologically active portion of a T139 protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Preferred biologically active polypeptides include one or more identified T139 structural domains, e.g., SCP-like domain (SEQ ID NO:5), C-type lectin domain (SEQ ID NO:6), or one of the EGF-like domains (SEQ ID NO:7 and 8).

Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native T139 protein. Preferred T139 protein has the amino acid

sequence shown of SEQ ID NO:2. Other useful T139 proteins are substantially identical to SEQ ID NO:2 and retain the functional activity of the protein of SEQ ID NO:2 yet differ in amino acid sequence due to natural 5 allelic variation or mutagenesis. Accordingly, a useful T139 protein is a protein which includes an amino acid sequence at least about 45%, preferably 55%, 65%, 75%, 85%, 95%, or 99% identical to the amino acid sequence of SEQ ID NO:2 and retains the functional activity of the 10 T139 proteins of SEQ ID NO:2. In other instances, the T139 protein is a protein having an amino acid sequence 55%, 65%, 75%, 85%, 95%, or 98% identical to the SCP-like, C-type lectin, or EGF-like domain (any one of SEQ ID NOS:5-8). In a preferred embodiment, the T139 protein 15 retains the functional activity of the T139 protein of SEQ ID NO:2.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can 20 be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position 25 in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical 30 positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions x 100).

The determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a 35 mathematical algorithm utilized for the comparison of two

- 29 -

sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the 5 NBLAST and XBLAST programs of Altschul et al. (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to T139 nucleic acid molecules of the invention. BLAST 10 protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to T139 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in 15 Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See  
<http://www.ncbi.nlm.nih.gov>. Another preferred, non- 20 limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing 25 the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

The percent identity between two sequences can be determined using techniques similar to those described 30 above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

The invention also provides T139 chimeric or fusion proteins. As used herein, a T139 "chimeric protein" or "fusion protein" comprises a T139 polypeptide 35 operatively linked to a non-T139 polypeptide. A "T139

- 30 -

polypeptide" refers to a polypeptide having an amino acid sequence corresponding to T139, whereas a "non-T139 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not 5 substantially identical to the T139 protein, e.g., a protein which is different from the T139 protein and which is derived from the same or a different organism. Within a T139 fusion protein the T139 polypeptide can correspond to all or a portion of a T139 protein, 10 preferably at least one biologically active portion of a T139 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the T139 polypeptide and the non-T139 polypeptide are fused in-frame to each other. The non-T139 polypeptide can be 15 fused to the N-terminus or C-terminus of the T139 polypeptide.

One useful fusion protein is a GST-T139 fusion protein in which the T139 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can 20 facilitate the purification of recombinant T139.

In another embodiment, the fusion protein is a T139 protein containing a heterologous signal sequence at its N-terminus. For example, the native T139 signal sequence (i.e., about amino acids 1 to 22 of SEQ ID NO:2) 25 can be removed and replaced with a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of T139 can be increased through use of a heterologous signal sequence. For example, the gp67 secretory sequence of the 30 baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of 35 melittin and human placental alkaline phosphatase

- 31 -

(Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (*Molecular cloning, Sambrook et al, second edition, Cold spring harbor 5 laboratory press, 1989*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

In yet another embodiment, the fusion protein is an T139-immunoglobulin fusion protein in which all or part of T139 is fused to sequences derived from a member 10 of the immunoglobulin protein family. (see, e.g., PCT Publication Number WO 88/07087 and Aruffo et al. (1990) Cell 61:1303-1313). The T139-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject 15 to inhibit an interaction between a T139 receptor and a T139 protein on the surface of a cell, to thereby suppress T139-mediated signal transduction *in vivo*. Inhibition of the T139 ligand/T139 interaction may be useful therapeutically for both the treatment of 20 proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the T139-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-T139 antibodies in a subject, to purify T139 receptors and in 25 screening assays to identify molecules which inhibit the interaction of T139 with its receptor.

Preferably, a T139 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the 30 different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as 35 appropriate, alkaline phosphatase treatment to avoid

undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene 5 fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., *Current Protocols in Molecular 10 Biology*, Ausubel et al. eds., John Wiley & Sons: 1992). Moreover, many expression vectors are commercially 15 available that already encode a fusion moiety (e.g., a GST polypeptide). An T139-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the T139 protein.

The present invention also pertains to variants of the T139 proteins which function as either T139 agonists (mimetics) or as T139 antagonists. Variants of the T139 protein can be generated by mutagenesis, e.g., discrete 20 point mutation or truncation of the T139 protein. An agonist of the T139 protein can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the T139 protein. An antagonist of the T139 protein can inhibit one or more of 25 the activities of the naturally occurring form of the T139 protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the T139 protein. Thus, specific biological effects can be elicited by treatment with a 30 variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the T139 proteins.

- 33 -

Variants of the T139 protein which function as either T139 agonists (mimetics) or as T139 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the T139 protein

5 for T139 protein agonist or antagonist activity. In one embodiment, a variegated library of T139 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of T139 variants can be produced by,

10 for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential T139 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage

15 display) containing the set of T139 sequences therein. There are a variety of methods which can be used to produce libraries of potential T139 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an

20 automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential T139 sequences. Methods for synthesizing

25 degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477).

30 In addition, libraries of fragments of the T139 protein coding sequence can be used to generate a variegated population of T139 fragments for screening and subsequent selection of variants of a T139 protein. In one embodiment, a library of coding sequence fragments

35 can be generated by treating a double stranded PCR

- 34 -

fragment of a T139 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include 5 sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which 10 encodes N-terminal and internal fragments of various sizes of the T139 protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA 15 libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of T139 proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening 20 large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates 25 isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify T139 variants (Arkin and 30 Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6(3):327-331).

An isolated T139 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind T139 using standard techniques for 35 polyclonal and monoclonal antibody preparation. The

- 35 -

full-length T139 protein can be used or, alternatively, the invention provides antigenic peptide fragments of T139 for use as immunogens. The antigenic peptide of T139 comprises at least 8 (preferably 10, 15, 20, or 30) 5 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 and encompasses an epitope of T139 such that an antibody raised against the peptide forms a specific immune complex with T139.

Preferred epitopes encompassed by the antigenic peptide are regions of T139 that are located on the surface of the protein, e.g., hydrophilic regions. A hydrophobicity analysis of the human T139 protein sequence indicates that the regions between, e.g., amino acids 125 and 140, between amino acids 265 and 280, and 15 between amino acids 315 and 335 of SEQ ID NO:2 are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production.

A T139 immunogen typically is used to prepare 20 antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed T139 protein or a chemically synthesized T139 polypeptide. The preparation 25 can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic T139 preparation induces a polyclonal anti-T139 antibody response.

30 Accordingly, another aspect of the invention pertains to anti-T139 antibodies. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen 35 binding site which specifically binds an antigen, such as

- 36 -

T139. A molecule which specifically binds to T139 is a molecule which binds T139, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains T139. Examples of 5 immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub>, fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind T139. The term "monoclonal" 10 antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of T139. A monoclonal antibody composition thus typically 15 displays a single binding affinity for a particular T139 protein with which it immunoreacts.

Polyclonal anti-T139 antibodies can be prepared as described above by immunizing a suitable subject with a T139 immunogen. The anti-T139 antibody titer in the 20 immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized T139. If desired, the antibody molecules directed against T139 can be isolated from the mammal (e.g., from the blood) and further 25 purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-T139 antibody titers are highest, antibody-producing cells can be obtained from the subject and used to 30 prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole et al. 35 (1985), *Monoclonal Antibodies and Cancer Therapy*, Alan R.

- 37 -

Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing various antibodies monoclonal antibody hybridomas is well known (see, e.g., *Current Protocols in Immunology* (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a T139 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds T139.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-T139 monoclonal antibody (see, e.g., *Current Protocols in Immunology*, *supra*; Galfre et al. (1977) *Nature* 266:55052; R.H. Kenneth, in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); and Lerner (1981) *Yale J. Biol. Med.*, 54:387-402. Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line, e.g., a myeloma cell line that is sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/0-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse

- 38 -

splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days 5 because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind T139, e.g., using a standard ELISA assay.

10        Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-T139 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with T139 to thereby isolate 15 immunoglobulin library members that bind T139. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP™ Phage Display Kit, Catalog No. 20 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT 25 Publication WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum.*

30        *Antibod. Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *EMBO J* 12:725-734.

35        Additionally, recombinant anti-T139 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are

- 39 -

within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 5 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Patent No. 4,816,567; European Patent Application 125,023; Better et al. (1988) *Science* 240:1041-1043; Liu et al. (1987) *Proc. 10 Natl. Acad. Sci. USA* 84:3439-3443; Liu et al. (1987) *J. Immunol.* 139:3521-3526; Sun et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura et al. (1987) *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al. (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, (1985) *Science* 229:1202-1207; Oi et al. (1986) *Bio/Techniques* 4:214; U.S. Patent 5,225,539; Jones et al. (1986) *Nature* 321:552-525; Verhoeyan et al. (1988) *Science* 239:1534; and Beidler et al. (1988) *J. Immunol.* 141:4053-4060.

20 An anti-T139 antibody (e.g., monoclonal antibody) can be used to isolate T139 by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-T139 antibody can facilitate the purification of natural T139 from cells and of recombinantly produced 25 T139 expressed in host cells. Moreover, an anti-T139 antibody can be used to detect T139 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the T139 protein. Anti-T139 antibodies can be used diagnostically 30 to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include 35 various enzymes, prosthetic groups, fluorescent

- 40 -

materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; 5 examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or 10 phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^{3}\text{H}$ .

15 III. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding T139 (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid 20 molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein 25 additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other 30 vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the

- 41 -

expression of genes to which they are operatively linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include 5 such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the 10 invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for 15 expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for 20 expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control 25 elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct 30 constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design 35 of the expression vector can depend on such factors as

- 42 -

the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including 5 fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., T139 proteins, mutant forms of T139, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of T139 in 10 prokaryotic or eukaryotic cells, e.g., bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, 15 Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most 20 often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the 25 recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity 30 purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion 35 protein. Such enzymes, and their cognate recognition

- 43 -

sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRITS 5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann et al., (1988) *Gene* 69:301-315) and pET 11d (Studier et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac 10 fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$  prophage harboring a T7 gn1 gene under the 15 transcriptional control of the lacUV 5 promoter.

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically 20 cleave the recombinant protein (Gottesman, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of 25 the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada et al. (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration 30 of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

- 44 -

In another embodiment, the T139 expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari et al. (1987) *EMBO J.* 6:229-234), pMFA (Kurjan 5 and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz et al. (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, CA), and picZ (InVitrogen Corp, San Diego, CA).

Alternatively, T139 can be expressed in insect 10 cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-15 39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 20 329:840) and pMT2PC (Kaufman et al. (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, 25 cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al. (*supra*).

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of 30 the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin 35 promoter (liver-specific; Pinkert et al. (1987) *Genes*

- 45 -

Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji et al. (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) *Science* 230:912-916), and 10 mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an 20 antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to T139 mRNA. Regulatory sequences operatively linked to a 25 nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue 30 specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the 35 activity of which can be determined by the cell type into

which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes See Weintraub et al., *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

5 Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the 10 particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are 15 still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, T139 protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or 20 mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or 25 transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-30 precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*supra*), and other laboratory manuals.

For stable transfection of mammalian cells, it is 35 known that, depending upon the expression vector and

transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to 5 antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a 10 host cell on the same vector as that encoding T139 or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, 15 while the other cells die).

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) T139 protein.

Accordingly, the invention further provides methods for 20 producing T139 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding T139 has been introduced) in a suitable medium such that T139 protein 25 is produced. In another embodiment, the method further comprises isolating T139 from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in 30 one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which T139-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous T139 sequences have been 35 introduced into their genome or homologous recombinant

- 48 -

animals in which endogenous T139 sequences have been altered. Such animals are useful for studying the function and/or activity of T139 and for identifying and/or evaluating modulators of T139 activity. As used 5 herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, 10 dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene 15 product in one or more cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous T139 gene has been altered by homologous recombination 20 between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing T139-encoding nucleic acid into 25 the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The T139 cDNA sequence e.g., that of (SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC 98694) can be 30 introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human T139 gene, such as a mouse T139 gene, can be isolated based on hybridization to the human T139 cDNA and used as a transgene. Intronic sequences and polyadenylation 35 signals can also be included in the transgene to increase

- 49 -

the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the T139 transgene to direct expression of T139 protein to particular cells. Methods for generating transgenic 5 animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse* 10 *Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the T139 transgene in its genome and/or expression of 15 T139 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding T139 can further be bred to other transgenic animals carrying 20 other transgenes.

To create an homologous recombinant animal, a vector is prepared which contains at least a portion of a T139 gene (e.g., a human or a non-human homolog of the T139 gene, e.g., a murine T139 gene) into which a 25 deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the T139 gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous T139 gene is functionally disrupted (i.e., no longer encodes a 30 functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous T139 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region 35 can be altered to thereby alter the expression of the

- 50 -

endogenous T139 protein). In the homologous recombination vector, the altered portion of the T139 gene is flanked at its 5' and 3' ends by additional nucleic acid of the T139 gene to allow for homologous 5 recombination to occur between the exogenous T139 gene carried by the vector and an endogenous T139 gene in an embryonic stem cell. The additional flanking T139 nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.

10 Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see e.g., Thomas and Capecchi (1987) *Cell* 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by 15 electroporation) and cells in which the introduced T139 gene has homologously recombined with the endogenous T139 gene are selected (see e.g., Li et al. (1992) *Cell* 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form 20 aggregation chimeras (see, e.g., Bradley in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the 25 embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing 30 homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Current Opinion in Bio/Technology* 2:823-829 and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

- 51 -

In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase 5 system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman et al. 10 (1991) *Science* 251:1351-1355. If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of 15 "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals 20 described herein can also be produced according to the methods described in Wilmut et al. (1997) *Nature* 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the 25 growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it 30 develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

- 52 -

IV. Pharmaceutical Compositions

The T139 nucleic acid molecules, T139 proteins, and anti-T139 antibodies (also referred to herein as "active compounds") of the invention can be incorporated 5 into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, 10 isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active 15 substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

20 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal 25 (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene 30 glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as 35 acetates, citrates or phosphates and agents for the

adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable 5 syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable 10 solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to 15 the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for 20 example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the 25 required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the 30 like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the

- 54 -

composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a T139 protein 5 or anti-T139 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a 10 sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and 15 freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in 20 gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier 25 for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and 30 the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a 35 lubricant such as magnesium stearate or Sterotes; a

- 55 -

glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. For administration by inhalation, the 5 compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by 10 transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, 15 detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as 20 generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

25 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, 30 biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be 35 obtained commercially from Alza Corporation and Nova

- 56 -

Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be 5 prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of 10 administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic 15 effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the 20 limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, 25 for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector 30 in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can

- 57 -

include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with 5 instructions for administration.

V. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening 10 assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology), c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic). A T139 15 protein interacts with other cellular proteins and can thus be used for (i) regulation of cellular proliferation; (ii) regulation of cellular differentiation; and (iii) regulation of cell survival. The isolated nucleic acid molecules of the invention can 20 be used to express T139 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect T139 mRNA (e.g., in a biological sample) or a genetic lesion in a T139 gene, and to modulate T139 activity. In addition, the T139 proteins 25 can be used to screen drugs or compounds which modulate the T139 activity or expression as well as to treat disorders characterized by insufficient or excessive production of T139 protein or production of T139 protein forms which have decreased or aberrant activity compared 30 to T139 wild type protein. In addition, the anti-T139 antibodies of the invention can be used to detect and isolate T139 proteins and modulate T139 activity.

- 58 -

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

A. Screening Assays

5 The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to T139 proteins or have a 10 stimulatory or inhibitory effect on, for example, T139 expression or T139 activity.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a T139 polypeptide or 15 biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution 20 phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other 25 four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: 30 DeWitt et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al. (1994). *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell et

al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop et al. (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Bio/Techniques* 13:412-5 421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:1865-1869) or on phage (Scott and Smith 10 (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla et al. (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; and Felici (1991) *J. Mol. Biol.* 222:301-310).

In one embodiment, an assay is a cell-based assay 15 in which a cell which expresses T139 protein, or a biologically active portion thereof, is contacted with a test compound and the ability of the test compound to bind to a T139 protein determined. The cell, for example, can be a yeast cell or a cell of mammalian 20 origin. Determining the ability of the test compound to bind to the T139 protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the T139 protein or biologically active 25 portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation 30 counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In a preferred 35 embodiment, the assay comprises contacting a cell which

- 60 -

expresses a T139 protein, or a biologically active portion thereof, with a known compound which binds T139 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the 5 test compound to interact with a T139 protein, wherein determining the ability of the test compound to interact with a T139 protein comprises determining the ability of the test compound to preferentially bind to T139 or a biologically active portion thereof as compared to the 10 known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a T139 protein, or a biologically active portion thereof, with a test compound and determining the ability of the test 15 compound to modulate (e.g., stimulate or inhibit) the activity of the T139 protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of T139 or a biologically active portion thereof can be accomplished, 20 for example, by determining the ability of the T139 protein to bind to or interact with a T139 target molecule. As used herein, a "target molecule" is a molecule with which a T139 protein binds or interacts in nature, for example, a T139 receptor, a molecule in the 25 extracellular milieu, or a molecule associated with the external surface of a cell membrane. A T139 target molecule can be a non-T139 molecule or a T139 protein or polypeptide of the present invention. In one embodiment, a T139 target molecule is a component of a signal 30 transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a T139 molecule to its receptor) through the cell membrane and into the cell.

Determining the ability of the T139 protein to 35 bind to or interact with a T139 target molecule can be

- 61 -

accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the T139 protein to bind to or interact with a T139 target molecule can be accomplished 5 by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., intracellular  $Ca^{2+}$ , diacylglycerol, IP3, etc.), detecting catalytic/enzymatic 10 activity of the target an appropriate substrate, detecting the induction of a reporter gene (e.g., a T139-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g. luciferase), or detecting a cellular response, for 15 example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a T139 protein or biologically active portion thereof with 20 a test compound and determining the ability of the test compound to bind to the T139 protein or biologically active portion thereof. Binding of the test compound to the T139 protein can be determined either directly or indirectly as described above. In a preferred 25 embodiment, the assay includes contacting the T139 protein or biologically active portion thereof with a known compound which binds T139 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact 30 with a T139 protein, wherein determining the ability of the test compound to interact with a T139 protein comprises determining the ability of the test compound to preferentially bind to T139 or biologically active portion thereof as compared to the known compound.

- 62 -

In another embodiment, an assay is a cell-free assay comprising contacting T139 protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate 5 (e.g., stimulate or inhibit) the activity of the T139 protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of T139 can be accomplished, for example, by determining the ability of the T139 protein to bind to a 10 T139 target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of T139 can be accomplished by determining the ability of the T139 protein further 15 modulate a T139 target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.

In yet another embodiment, the cell-free assay 20 comprises contacting the T139 protein or biologically active portion thereof with a known compound which binds T139 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a T139 protein, 25 wherein determining the ability of the test compound to interact with a T139 protein comprises determining the ability of the T139 protein to preferentially bind to or modulate the activity of a T139 target molecule.

In some cell-based assays, it may be desirable to 30 utilize a solubilizing agent such that a membrane-bound form of T139 is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltose, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, 35 Triton® X-100, Triton® X-114, Thesit®,

- 63 -

Isotridecypoly(ethylene glycol ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either T139 or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to T139, or interaction of T139 with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/T139 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or T139 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of T139 binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on  
matrices can also be used in the screening assays of the  
invention. For example, either T139 or its target  
molecule can be immobilized utilizing conjugation of  
5 biotin and streptavidin. Biotinylated T139 or target  
molecules can be prepared from biotin-NHS (N-hydroxy-  
succinimide) using techniques well known in the art  
(e.g., biotinylation kit, Pierce Chemicals; Rockford,  
IL), and immobilized in the wells of streptavidin-coated  
10 96 well plates (Pierce Chemical). Alternatively,  
antibodies reactive with T139 or target molecules but  
which do not interfere with binding of the T139 protein  
to its target molecule can be derivatized to the wells of  
the plate, and unbound target or T139 trapped in the  
15 wells by antibody conjugation. Methods for detecting  
such complexes, in addition to those described above for  
complexes using antibodies reactive with the T139 or  
target molecule, as well as enzyme-linked assays which  
20 rely on detecting an enzymatic activity associated with  
the T139 or target molecule.

In another embodiment, modulators of T139  
expression are identified in a method in which a cell is  
25 contacted with a candidate compound and the expression of  
T139 mRNA or protein in the cell is determined. The  
level of expression of T139 mRNA or protein in the  
presence of the candidate compound and the expression of  
30 the absence of the candidate compound are compared to the  
level of expression of T139 mRNA or protein in the  
absence of the candidate compound. The candidate  
compound can then be identified as a modulator of the  
expression based on this comparison. For example, when  
35 the expression of T139 mRNA or protein is greater  
(statistically significantly greater) in the presence of  
the candidate compound than in its absence, the candidate  
compound is identified as a stimulator of T139 mRNA or

- 65 -

protein expression. Alternatively, when expression of T139 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an 5 inhibitor of T139 mRNA or protein expression. The level of T139 mRNA or protein expression in the cells can be determined by methods described herein for detecting T139 mRNA or protein.

In yet another aspect of the invention, the T139 10 proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) *Cell* 72:223-232; Madura et al. (1993) *J. Biol. Chem.* 268:12046-12054; Bartel et al. (1993) *Bio/Techniques* 14:920-924; Iwabuchi et al. 15 (1993) *Oncogene* 8:1693-1696; and WO 94/10300), to identify other proteins, which bind to or interact with T139 ("T139-binding proteins" or "T139-bp") and modulate T139 activity. Such T139-binding proteins are also likely to be involved in the propagation of signals by 20 the T139 proteins as, for example, upstream or downstream elements of the T139 pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, 25 the assay utilizes two different DNA constructs. In one construct, the gene that codes for T139 is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA 30 sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an T139-dependent complex, the DNA- 35 binding and activation domains of the transcription

- 66 -

factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression 5 of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with T139.

This invention further pertains to novel agents 10 identified by the above-described screening assays and uses thereof for treatments as described herein.

#### B. Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene 15 sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute 20 biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

##### 1. Chromosome Mapping

Once the sequence (or a portion of the sequence) 25 of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, T139 nucleic acid molecules described herein or fragments thereof, can be used to map the location of 30 T139 genes on a chromosome. The mapping of the T139 sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, T139 genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the T139 sequences. Computer analysis of T139 sequences can be used to rapidly select primers that do 5 not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to 10 the T139 sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in 15 random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels 20 of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio et al. 25 (1983) *Science* 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid 30 procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the T139 sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments 35 from specific chromosomes. Other mapping strategies

which can similarly be used to map a T139 sequence to its chromosome include *in situ* hybridization (described in Fan et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and 5 pre-selection by hybridization to chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one 10 step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands 15 develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location 20 with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., *Human Chromosomes: A Manual of Basic Techniques* 25 (Pergamon Press, New York, 1988).

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. 30 Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

- 69 -

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V.

5 McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent 10 genes), described in, e.g., Egeland et al. (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the T139 gene can be determined. If a 15 mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking 20 for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the 25 presence of a mutation and to distinguish mutations from polymorphisms.

## 2. Tissue Typing

The T139 sequences of the present invention can also be used to identify individuals from minute 30 biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and

- 70 -

probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification 5 difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an alternative technique 10 which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the T139 sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's 15 DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic 20 differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The T139 sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the 25 coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used 30 as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate 35 individuals. The noncoding sequences of SEQ ID NO:1 can comfortably provide positive individual identification

- 71 -

with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3 are used, a more appropriate number of primers for 5 positive individual identification would be 500-2,000.

If a panel of reagents from T139 sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that 10 individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

### 3. Use of Partial T139 Sequences in Forensic Biology

15 DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To 20 make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a 25 standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can 30 enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for

- 72 -

identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1 are particularly appropriate for this use as greater 5 numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the T139 sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:1 having 10 a length of at least 20 or 30 bases.

The T139 sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an *in situ* hybridization technique, to identify a specific 15 tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such T139 probes can be used to identify tissue by species and/or by organ type.

20 In a similar fashion, these reagents, e.g., T139 primers or probes can be used to screen tissue culture for contamination (i.e., screen for the presence of a mixture of different types of cells in a culture).

#### C. Predictive Medicine

25 The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. 30 Accordingly, one aspect of the present invention relates to diagnostic assays for determining T139 protein and/or nucleic acid expression as well as T139 activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual

- 73 -

is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant T139 expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether 5 an individual is at risk of developing a disorder associated with T139 protein, nucleic acid expression or activity. For example, mutations in a T139 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby 10 prophylactically treat an individual prior to the onset of a disorder characterized by or associated with T139 protein, nucleic acid expression or activity.

Another aspect of the invention provides methods for determining T139 protein, nucleic acid expression or 15 T139 activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment 20 of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to 25 monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of T139 in clinical trials.

These and other agents are described in further detail in the following sections.

30. 1. Diagnostic Assays

An exemplary method for detecting the presence or absence of T139 in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable

of detecting T139 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes T139 protein such that the presence of T139 is detected in the biological sample. A preferred agent for detecting T139 mRNA or genomic DNA is 5 a labeled nucleic acid probe capable of hybridizing to T139 mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length T139 nucleic acid, such as the nucleic acid of SEQ ID NO: 1 or 3, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 10 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to T139 mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

15 A preferred agent for detecting T139 protein is an antibody capable of binding to T139 protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')), can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) 20 a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by 25 reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended 30 to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect T139 mRNA, 35 protein, or genomic DNA in a biological sample *in vitro*.

- 75 -

as well as *in vivo*. For example, *in vitro* techniques for detection of T139 mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of T139 protein include enzyme linked 5 immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of T139 genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of T139 protein include introducing into a 10 subject a labeled anti-T139 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains 15 protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means 20 from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting T139 protein, mRNA, or genomic 25 DNA, such that the presence of T139 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of T139 protein, mRNA or genomic DNA in the control sample with the presence of T139 protein, mRNA or genomic DNA in the test sample.

30 The invention also encompasses kits for detecting the presence of T139 in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of T139. 35 For example, the kit can comprise a labeled compound or

agent capable of detecting T139 protein or mRNA in a biological sample and means for determining the amount of T139 in the sample (e.g., an anti-T139 antibody or an oligonucleotide probe which binds to DNA encoding T139, 5 e.g., SEQ ID NO:1 or SEQ ID NO:3). Kits may also include instruction for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of T139 if the amount of T139 protein or mRNA is above or below a normal level.

10 For antibody-based kits, the kit may comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to T139 protein; and, optionally, (2) a second, different antibody which binds to T139 protein or the first antibody and is conjugated to a 15 detectable agent.

For oligonucleotide-based kits, the kit may comprise, for example: (1) a oligonucleotide, e.g., a detectably labelled oligonucleotide, which hybridizes to a T139 nucleic acid sequence or (2) a pair of primers 20 useful for amplifying a T139 nucleic acid molecule.

The kit may also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit may also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a 25 substrate). The kit may also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a 30 single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression or activity of T139.

## 2. Prognostic Assays

The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant T139 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with T139 protein, nucleic acid expression or activity.

Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder. Thus, the present invention provides a method in which a test sample is obtained from a subject and T139 protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of T139 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant T139 expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant T139 expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease T139 activity). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a

disorder associated with aberrant T139 expression or activity in which a test sample is obtained and T139 protein or nucleic acid is detected (e.g., wherein the presence of T139 protein or nucleic acid is diagnostic 5 for a subject that can be administered the agent to treat a disorder associated with aberrant T139 expression or activity).

The methods of the invention can also be used to detect genetic lesions or mutations in a T139 gene, 10 thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a 15 genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a T139-protein, or the mis-expression of the T139 gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of 1) a 20 deletion of one or more nucleotides from a T139 gene; 2) an addition of one or more nucleotides to a T139 gene; 3) a substitution of one or more nucleotides of a T139 gene, 4) a chromosomal rearrangement of a T139 gene; 5) an alteration in the level of a messenger RNA transcript of 25 a T139 gene, 6) aberrant modification of a T139 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a T139 gene, 8) a non-wild type level of a T139-protein, 9) allelic loss of a T139 30 gene, and 10) inappropriate post-translational modification of a T139-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a T139 gene. A preferred biological sample is a peripheral

- 79 -

blood leukocyte sample isolated by conventional means from a subject.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain 5 reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) *Science* 241:1077-1080; and Nakazawa et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:360-10 364), the latter of which can be particularly useful for detecting point mutations in the T139-gene. (see Abravaya et al. (1995) *Nucleic Acids Res.* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., 15 genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a T139 gene under conditions such that hybridization and amplification of the T139-gene (if present) occurs, and detecting the 20 presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with 25 any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional 30 amplification system (Kwoh, et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) *Bio/Technology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques 35 well known to those of skill in the art. These detection

- 80 -

schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a T139 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in T139 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) *Human Mutation* 7:244-255; Kozal et al. (1996) *Nature Medicine* 2:753-759). For example, genetic mutations in T139 can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al. *supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to

the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the T139 gene and detect mutations by comparing the sequence of the sample T139 with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) *Proc. Natl. Acad. Sci. USA* 74:560) or Sanger ((1977) *Proc. Natl. Acad. Sci. USA* 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Bio/Techniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101; Cohen et al. (1996) *Adv. Chromatogr.* 36:127-162; and Griffin et al. (1993) *Appl. Biochem. Biotechnol.* 38:147-159).

Other methods for detecting mutations in the T139 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) *Science* 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type T139 sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and

with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation.

5 See, e.g., Cotton et al (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba et al (1992) *Methods Enzymol.* 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage 10 reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in T139 cDNAs obtained from samples of cells. For example, the *mutY* 15 enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a T139 sequence, e.g., a wild-type T139 20 sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

25 In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in T139 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant 30 and wild type nucleic acids (Orita et al. (1989) *Proc Natl. Acad. Sci USA*: 86:2766; see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control T139 nucleic acids will be denatured 35 and allowed to renature. The secondary structure of

single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected 5 with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double 10 stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) *Trends Genet* 7:5).

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing 15 a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of 20 approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

25 Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the 30 known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) *Nature* 324:163); Saiki et al. (1989) *Proc. Natl Acad. Sci USA* 86:6230). Such allele specific oligonucleotides are 35 hybridized to PCR amplified target DNA or a number of

different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification 5 technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on 10 differential hybridization) (Gibbs et al. (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition, it may be desirable to 15 introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany 20 (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of 25 amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, 30 e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a T139 gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which T139 is expressed

- 85 -

may be utilized in the prognostic assays described  
herein.

3. Pharmacogenomics  
Agents, or modulators which have a stimulatory or  
inhibitory effect on T139 activity (e.g., T139 gene  
expression) as identified by a screening assay described  
herein can be administered to individuals to treat  
(prophylactically or therapeutically) disorders (e.g., an  
immunological disorder) associated with aberrant T139  
activity. In conjunction with such-treatment, the  
pharmacogenomics (i.e., the study of the relationship  
between an individual's genotype and that individual's  
response to a foreign compound or drug) of the individual  
may be considered. Differences in metabolism of  
therapeutics can lead to severe toxicity or therapeutic  
failure by altering the relation between dose and blood  
concentration of the pharmacologically active drug. Thus,  
the pharmacogenomics of the individual permits the  
selection of effective agents (e.g., drugs) for  
prophylactic or therapeutic treatments based on a  
consideration of the pharmacogenomics of the individual's  
pharmacogenomics can further be used to determine  
appropriate dosages and therapeutic regimens.  
Accordingly, the activity of T139 protein, expression of  
T139 nucleic acid, or mutation content of T139 genes in  
an individual can be determined to thereby select  
appropriate agent(s) for therapeutic or prophylactic  
treatment of the individual.

Pharmacogenomics deals with clinically significant  
hereditary variations in the response to drugs due to  
altered drug disposition and abnormal action in affected  
persons. See, e.g., Linder (1997) Clin. Chem.  
43 (2):254-266. In general, two types of pharmacogenetic  
conditions can be differentiated. Genetic conditions

transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These 5 pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant 10 drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery 15 of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious 20 toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the 25 gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they 30 receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do 35 not respond to standard doses. Recently, the molecular

basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of T139 protein, expression of T139 nucleic acid, or mutation content of T139 genes in 5 an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes 10 to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a 15 T139 modulator, such as a modulator identified by one of the exemplary screening assays described herein.

#### 4. Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of T139 (e.g., 20 the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase T139 gene 25 expression, protein levels, or upregulate T139 activity, can be monitored in clinical trials of subjects exhibiting decreased T139 gene expression, protein levels, or downregulated T139 activity. Alternatively, the effectiveness of an agent determined by a screening 30 assay to decrease T139 gene expression, protein levels, or downregulated T139 activity, can be monitored in clinical trials of subjects exhibiting increased T139 gene expression, protein levels, or upregulated T139 activity. In such clinical trials, the expression or

activity of T139 and, preferably, other genes that have been implicated in, for example, a cellular proliferation disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

5 For example, and not by way of limitation, genes, including T139, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates T139 activity (e.g., identified in a screening assay as described herein) can be identified.

10 Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of T139 and other genes implicated in the disorder. The levels of gene

15 expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity

20 of T139 or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent.

Accordingly, this response state may be determined before, and at various points during, treatment of the

25 individual with the agent.

In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a T139 protein, mRNA, or genomic DNA in the preadministration sample;

- 89 -

(iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the T139 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the T139 protein, mRNA, or genomic DNA in the pre-administration sample with the T139 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly.

5 For example, increased administration of the agent may be desirable to increase the expression or activity of T139 to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease

10 expression or activity of T139 to lower levels than detected, i.e., to decrease the effectiveness of the agent.

15

15 expression or activity of T139 to lower levels than detected, i.e., to decrease the effectiveness of the agent.

C. Methods of Treatment

The present invention provides for both

20 prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant T139 expression or activity. Such disorders include kidney defects such as kidney failure or hyperplasia.

25 1. Prophylactic Methods

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant T139 expression or activity, by administering to the subject an agent which modulates T139 expression or at least one T139 activity. Subjects at risk for a disease which is caused or contributed to by aberrant T139 expression or activity can be identified by, for example, any or a combination of diagnostic or

- 90 -

prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the T139 aberrancy, such that a disease or disorder is prevented or, 5 alternatively, delayed in its progression. Depending on the type of T139 aberrancy, for example, a T139 agonist or T139 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

10           2. Therapeutic Methods

Another aspect of the invention pertains to methods of modulating T139 expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that 15 modulates one or more of the activities of T139 protein activity associated with the cell. An agent that modulates T139 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a T139 protein, a 20 peptide, a T139 peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of T139 protein. Examples of such stimulatory agents include active T139 protein and a nucleic acid molecule encoding T139 that has been 25 introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of T139 protein. Examples of such inhibitory agents include antisense T139 nucleic acid molecules and anti-T139 antibodies. These modulatory methods can be 30 performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant

- 91 -

expression or activity of a T139 protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of 5 agents that modulates (e.g., upregulates or downregulates) T139 expression or activity. In another embodiment, the method involves administering a T139 protein or nucleic acid molecule as therapy to compensate for reduced or aberrant T139 expression or activity.

10 Stimulation of T139 activity is desirable in situations in which T139 is abnormally downregulated and/or in which increased T139 activity is likely to have a beneficial effect. Conversely, inhibition of T139 activity is desirable in situations in which T139 is 15 abnormally upregulated and/or in which decreased T139 activity is likely to have a beneficial effect.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and 20 published patent applications cited throughout this application are hereby incorporated by reference.

#### EXAMPLES

Example 1: Isolation and Characterization of Human T139 cDNA

25 RNA was isolated from human fetal kidney tissue, and the polyA+ fraction was purified using Oligotex beads (Qiagen). Three micrograms of polyA+ RNA were used to synthesize a cDNA library using the Superscript cDNA Synthesis kit (Gibco BRL; Gaithersburg, MD). 30 Complementary DNA was directionally cloned into the expression plasmid pMET7 using the SalI and NotI sites in the polylinker to construct a plasmid library. Transformants were picked and grown for single-pass

- 92 -

sequencing. One cDNA clone (jthKall15e09) was identified that encoded a protein with homology to testis-specific protein-1 (TPX-1), an acrosomal sperm protein that is a member of the SCP-like family of cysteine-rich secreted 5 proteins. JthKall15e09 contains an open reading frame of 446 amino acids, which is referred to as "Tango 139".

**Example 2: Distribution of T139 mRNA in Human Tissues**

The expression of T139 was analyzed using Northern blot hybridization. Oligonucleotide primers (5' 10 CCATGCTGCATCCAGAG 3' (SEQ ID NO:14); 5' CACAGACAAAGGCTTCTATC 3' (SEQ ID NO:15)) were used to amplify a 543 bp fragment from the coding region of jthKall14e09, and the DNA was radioactively labeled with  $^{32}$ P-dCTP using a Prime-It kit (Stratagene, La Jolla, CA) 15 according to the supplier's instructions. Filters containing human mRNA (MTNI and MTNII from Clontech, Palo Alto, CA) were probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to manufacturer's recommendations.

20 Tango 139 is expressed at high levels as a transcript of about 2.0 kb in the kidney, with lower levels in the testis. In addition, there are additional transcripts in both kidney and testis at about 2.4 and 3.5 kb. No other tissues examined (heart, brain, 25 placenta, lung, liver, skeletal muscle, pancreas, spleen, thymus, ovaries, small intestine, colon and peripheral blood leukocytes) showed any expression.

**Example 3: Characterization of T139 Proteins**

In this example, the predicted amino acid sequence 30 of human T139 protein was compared to amino acid sequences of known proteins and various motifs were identified. In addition, the molecular weight of the human T139 protein was predicted.

- 93 -

The human T139 cDNA isolated as described above (Figure 1; SEQ ID NO:1) encodes a 446 amino acid protein (Figure 1; SEQ ID NO:2). The signal peptide prediction program SIGNALP (Nielsen et al. (1997) *Protein Engineering* 10:1-6) predicted that T139 includes a 26 amino acid signal peptide (amino acid 1 to about amino acid 26 of SEQ ID NO:2) preceding the 420 amino acid mature protein (about amino acid 27 to amino acid 446; SEQ ID NO:4). A hydropathy plot of T139 is presented in 5 Figure 3. This plot shows the location of cysteines ("cys"; short vertical lines-just below plot) and the PFAM identifiers (PF00188, PF00008, and PF00059; bars just above plot). For general information regarding PFAM identifiers refer to Sonnhammer et al. (1997) *Protein 10 15 20 25 30 35* 28:405-420 and <http://www.psc.edu/general/software/packages/pfam/pfam.html>.

As shown in Figure 2A, T139 has a region of homology (amino acids 47 to 190, of SEQ ID NO:2; SEQ ID NO:5) to a SCP-like domain consensus sequence (PF00188, 20 of SEQ ID NO:2; SEQ ID NO:9). Figure 2B shows the region of homology (amino acids 297 to 412, SEQ ID NO:2; SEQ ID NO:6) to the C-type lectin domain consensus sequence (PF00059, SEQ ID NO:10). Although significant homology was observed, the four cysteines in this region of T139 25 do not match the four conserved cysteines in the consensus sequence; the alignment only recognized three of the four cysteines in this region of T139 as identical to the consensus cysteines. Figure 2C shows the regions of homology (amino acids 232 to 260 of SEQ ID NO:2; 30 (EGF1) and 264 to 291 of SEQ ID NO:2; (EGF2); SEQ ID NOS:7 and 8, respectively) to a EGF-like domain consensus sequence (PF00008, SEQ ID NO:11). Although both the EGF1 and EGF2 domains contain six cysteines as does the consensus, the alignment only recognizes five cysteines 35 as matching the consensus. Mature T139 has a predicted

- 94 -

MW of 49 kDa (47 kDa with the signal peptide removed), not including post-translational modifications. A signal peptide is predicted to exist from amino acids 1 to 26, using the prediction program SIGNALP (Nielsen et al.

5 (1997) *Protein Engineering* 10:1-6).

As noted above, T139 is homologous to testis-specific protein-1 (TPX-1; Kasahara et al. (1989) *Genomics* 5:527-34). TPX-1 is a testis-specific protein that is expressed by spermatogenic cells and is thought 10 to cause spermatogenic cells to bind to somatic Sertoli cells. Sertoli cells are essential for the proliferation, differentiation, and survival of spermatogenic cells. Human TPX-1 is a member of the CRISP family. Members of this family have a cysteine-rich 15 C-terminal region having the pattern CX<sub>8</sub>CX<sub>8</sub>CX<sub>8</sub>CX<sub>8</sub>C (Foster and Gerton (1996) *Mol. Reprod. Dev.* 44:221-29; Kratzch et al. (1996) *Eur. J. Biochem.* 236:827-36). Another member of this family is acidic epididymal 20 glycoprotein (AEG). This protein is present on the surface of the plasma membrane at the sperm head and is thought to be involved in sperm-egg fusion (Brooks and Tiver (1983) *J. Reprod. Fertil.* 69:650-57).

Based on the homology between T139 and TPX-1 and the expression of T139 in testis, T139 may play a role in 25 spermatogenesis and other testicular functions.

Accordingly, T139 nucleic acids, polypeptides, and modulators of T139 expression or activity can be used to modulate spermatogenesis or sperm-egg fusion. In addition, such molecules may be useful for treatment of a 30 variety of testicular disorders, e.g., testicular cancer.

**Example 4: Preparation of T139 Proteins**

Recombinant T129 can be produced in a variety of expression systems. For example, the mature T129 peptide can be expressed as a recombinant glutathione-S-

- 95 -

transferase (GST) fusion protein in *E. coli* and the fusion protein can be isolated and characterized.

Specifically, as described above, T129 can be fused to GST and this fusion protein can be expressed in *E. coli*

5 strain PEB199. Expression of the GST-T129 fusion protein in PEB199 can be induced with IPTG. The recombinant fusion protein can be purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads.

10 Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such 15 equivalents are intended to be encompassed by the following claims.

- 96 -

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:
  - a) a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694, or a complement thereof;
  - b) a nucleic acid molecule comprising a fragment of at least 250 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694, or a complement thereof;
  - c) nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694;
  - d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4 or the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694; and
  - e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions.

- 97 -

2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:

- a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, or the cDNA 5 insert of the plasmid deposited with ATCC as Accession Number 98694, or a complement thereof; and
- b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by 10 the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694.

3. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.

4. The nucleic acid molecule of claim 1 further 15 comprising nucleic acid sequences encoding a heterologous polypeptide.

5. A host cell which contains the nucleic acid molecule of claim 1.

6. The host cell of claim 4 which is a mammalian 20 host cell.

7. A non-human mammalian host cell containing the nucleic acid molecule of claim 1.

8. An isolated polypeptide selected from the group consisting of:

25 a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4;

- 98 -

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as 5 Accession Number 98694, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions;

c) a polypeptide which is encoded by a nucleic 10 acid molecule comprising a nucleotide sequence which is at least 55% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.

9. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:2 or SEQ 15 ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694.

10. The polypeptide of claim 8 further comprising heterologous amino acid sequences.

20 11. An antibody which selectively binds to a polypeptide of claim 8.

12. A method for producing a polypeptide selected from the group consisting of:

a) a polypeptide comprising the amino acid 25 sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694;

b) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an 30 amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694,

- 99 -

wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694; and

5 c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98694, wherein the polypeptide is  
10 encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions;

comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is  
15 expressed.

13. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession  
20 Number 98694.

14. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:

a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and

25 b) determining whether the compound binds to the polypeptide in the sample.

15. The method of claim 14, wherein the compound which binds to the polypeptide is an antibody.

16. A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.  
30

- 100 -

17. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
- 5 b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

18. The method of claim 17, wherein the sample 10 comprises mRNA molecules and is contacted with a nucleic acid probe.

19. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

15 20. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; 20 and
- b) determining whether the polypeptide binds to the test compound.

21. The method of claim 20, wherein the binding of the test compound to the polypeptide is detected by a 25 method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- 30 c) detection of binding using an assay for EGF or calcium-dependent carbohydrate recognition activity.

- 101 -

22. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a 5 sufficient concentration to modulate the activity of the polypeptide.

23. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:

10 a) contacting a polypeptide of claim 8 with a test compound; and  
b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

GTG GACCCACCGTCCGGCTCCATCCP	GCCTGAGAAAACAAGCCGGTGGCTGAGCCAGG	GTGCACGGAGTGCCTGAC	79	
GGGCCCACAGACCC	ATG CTG CAT CCA GAG ACC TCC CCT GCC CGG GGG CAT CTC CTG GCT GTG	Met Leu His Pro Glu Thr Ser Pro Gly Arg Gly His Leu Leu Ala Val	142	
1	5	10	15	
CTC CTG GCC CTC CTT GGC ACC GCC TGG GCA GAG GTG TGG CCA CCC CAG CTG CAG GAG CAG	202			
Leu Leu Ala Leu Leu Gly Thr Ala Trp Ala Glu Val Trp Pro Pro Gln Leu Gln Gln	25	30	35	
GCT CCG ATG GCC GGA GCC CTG AAC AGG AAG GAG AGT TTC TTG CTC CTC TCC CTG CAC AAC	262			
Ala Pro Met Ala Gly Ala Leu Asn Arg Lys Glu Ser Phe Leu Leu Ser Leu His Asn	40	45	50	55
CGC CTG CGC AGC TGG GTC CAG CCC CCT GCG GCT GAC ATG CGG AGG CTG GAC TGG AGT GAC	322			
Arg Leu Arg Ser Trp Val Gln Pro Pro Ala Ala Asp Met Arg Arg Leu Asp Trp Ser Asp	60	65	70	75
AGC CTG GCC CAA CTG GCT CAA GCC AGG GCA GCC CTC TGT GGA ATC CCA ACC CCG AGC CTG	382			
Ser Leu Ala Gln Leu Ala Gln Ala Arg Ala Leu Cys Gly Ile Pro Thr Pro Ser Leu	80	85	90	95
GCG TCC GGC CTG TGG CGC ACC CTG CAA GTG GGC TGG AAC ATG CAG CTG CTG CCC GCG GGC	442			
Ala Ser Gly Leu Trp Arg Thr Leu Gln Val Gly Trp Asn Met Gln Leu Leu Pro Ala Gly	100	105	110	115
TTG GCG TCC TTT GTT GAA GTG GTC AGC CTA TGG TTT GCA GAG GGG CAG CGG TAC AGC CAC	502			
Leu Ala Ser Phe Val Glu Val Val Ser Leu Trp Phe Ala Glu Gly Gln Arg Tyr Ser His	120	125	130	135
GCG GCA GGA GAG TGT GCT CGC AAC GCC ACC TGC ACC CAC TAC ACG CAG CTC GTG TGG GCC	562			
Ala Ala Gly Glu Cys Ala Arg Asn Ala Thr Cys Thr His Tyr Thr Gln Leu Val Trp Ala	140	145	150	155
ACC TCA AGC CAG CTG GGC TGT GGG CGG CAC CTG TGC TCT GCA GGC CAG GCA GCG ATA GAA	622			
Thr Ser Ser Gln Leu Gly Cys Gly Arg His Leu Cys Ser Ala Gly Gln Ala Ala Ile Glu	160	165	170	175
GCC TTT GTC TGT GCC TAC TCC CCC GGA GGC AAC TGG GAG GTC AAC GGG AAG ACA ATC ATC	682			
Ala Phe Val Cys Ala Tyr Ser Pro Gly Gly Asn Trp Glu Val Asn Gly Lys Thr Ile Ile	180	185	190	195
CCC TAT AAG AAG GGT GCC TGG TGT TCG CTC TGC ACA GCC AGT GTC TCA GGC TGC TTC AAA	742			
Pro Tyr Lys Lys Gly Ala Trp Cys Ser Leu Cys Thr Ala Ser Val Ser Gly Cys Phe Lys	200	205	210	215
GCC TGG GAC CAT GCA GGG GGG CTC TGT GAG GTC CCC AGG AAT CCT TGT CGC ATG AGC TGC	802			
Ala Trp Asp His Ala Gly Gly Leu Cys Glu Val Pro Arg Asn Pro Cys Arg Met Ser Cys	220	225	230	235
CAG AAC CAT GGA CGT CTC AAC ATC AGC ACC TGC CAC TGC CAC TGT CCC CCT GGC TAC ACG	862			
Gln Asn His Gly Arg Leu Asn Ile Ser Thr Cys His Cys His Cys Pro Pro Gly Tyr Thr	240	245	250	255
GGC AGA TAC TGC CAA GTG AGG TGC AGC CTG CAG TGT GTG CAC GGC CGG TTC CGG GAG GAG	922			
Gly Arg Tyr Cys Gln Val Arg Cys Ser Leu Gln Cys Val His Gly Arg Phe Arg Glu Glu	260	265	270	275
GAG TGC TCG TGC GTC TGT GAC ATC GGC TAC GGG GGA GCC CAG TGT GCC ACC AAG GTG CAT	982			
Glu Cys Ser Cys Val Cys Asp Ile Gly Tyr Gly Ala Gln Cys Ala Thr Lys Val His	280	285	290	295
TTT CCC TTC CAC ACC TGT GAC CTG AGG ATC GAC GGA GAC TGC TTC ATG GTG TCT TCA GAG	1042			
Phe Pro Phe His Thr Cys Asp Leu Arg Ile Asp Gly Asp Cys Phe Met Val Ser Ser Glu	300	305	310	315
GCA GAC ACC TAT TAC AGA GCC AGG ATG AAA TGT CAG AGG AAA GGC GGG GTG CTG GCC CAG	1102			
Ala Asp Thr Tyr Tyr Arg Ala Arg Met Lys Cys Gln Arg Lys Gly Gly Val Leu Ala Gln	320	325	330	335

ATC AAG AGC CAG AAA GTG CAG GAC ATC CTC GCC TTC TAT CTG GGC CGC CTG GAG ACC ACC	1162
Ile Lys Ser Gln Lys Val Gln Asp Ile Leu Ala Phe Tyr Leu Gly Arg Leu Glu Thr Thr	
340 345 350 355	
AAC GAG GTG ATT GAC AGT GAC TTC GAG ACC AGG AAC TTC TGG ATC GGG CTC ACC TAC AAG	1222
Asn Glu Val Ile Asp Ser Asp Phe Glu Thr Arg Asn Phe Trp Ile Gly Leu Thr Tyr Lys	
360 365 370 375	
ACC GCC AAG GAC TCC TTC CGC TGG GCC ACA GGG GAG CAC CAG GCC TTC ACC AGT TTT GCC	1282
Thr Ala Lys Asp Ser Phe Arg Trp Ala Thr Gly Glu His Gln Ala Phe Thr Ser Phe Ala	
380 385 390 395	
TTT GGG CAG CCT GAC AAC CAC GGG TTT GGC AAC TGC GTG GAG CTG CAG GCT TCA GCT GCC	1342
Phe Gly Gln Pro Asp Asn His Gly Phe Gly Asn Cys Val Glu Leu Gln Ala Ser Ala Ala	
400 405 410 415	
TTC AAC TGG AAC AAC CAG CGC TGC AAA ACC CGA AAC CGT TAC ATC TGC CAG TTT GCC CAG	1402
Phe Asn Trp Asn Asn Gln Arg Cys Lys Thr Arg Asn Arg Tyr Ile Cys Gln Phe Ala Gln	
420 425 430 435	
GAG CAC ATC TCC CGG TGG GGC CCA GGG TCC TGA	1435
Glu His Ile Ser Arg Trp Gly Pro Gly Ser *	
440 445	
GGCCTGACCACATGGCTCCCTCGCCTGCCCTGGGAGCACCGGCTCTGCTTACCTGTCCGCCACCTGTCTGGAACAAAGG	1514
GCCAGGTTAACACCACATGCCCTCATGTCCAAAGAGGTCTCAGACCTTGCAACAATGCCAGAAGTTGGCAGAGAGAGGCA	1593
GGGAGGCCAGTGAGGGCCAGGGAGTGAGTGTTAGAAGAAGCTGGGCCCTTCGCTCTTGTGATTGGGAAGATGGCT	1672
TCAATTAGATGGCAAAGGAGAGGACACCGCCAGTGGTCAAAAAGGCTGCTCTTCCACCTGGCCAGACCCCTGTGGG	1751
GCAGCGGAGCTTCCCTGTGGCATGAACCCCACAGGGTAITAAATTATGAATCAGCTGAAAAAAAAAAAAAA	1830
AAAAAAAAAAAAAGGGCGGCCGC	1856

FIG. 1 (cont.)

T1139pro	177	AFVCAYSPGGGNWEV	VC Y P+GN+	YYVCNYCPRGNYmN*
				190

FIG. 2A

		*CP...dwi.YegHCYWI fgerKTWeEAeeYCQrMrPGgHLVSIQNWEEN	
		P + G C+++ +E T + A++ CQR+ GG L+ I ++ +	
T139pro	297	FPPHTCDLRIDGDCFMVSSEADTYYRARMKCQRK--GGVLAQIKSQKVQ	343
		dFIqslvkyN.....YyWIGLrDintEWnWeWmDGtYPMNY	
		D ++ + + +WIGL++ + + + +W +G+ + +	
T139pro	344	DILAFYLGRLETTNEVIDSDDFETRNFWIGLTYKTAKDSFRWATGE-HQAF	392
		tNWapgEPNNnngnnEDCVEMY*	
		T A G+P+N + +CVE++	
T139pro	393	TSFAFGQPDN-HGFGNCVELQ	412

FIG. 2B

			*CnqNPGtCvNtpmYtciCpeGYmyYtGrrC*
			C + C+N+G+ + + + +C+CP+G
			YTGR C
			CRM-SCQNHGLNIS-TCHCHCPG---YTGRYC
			260
			Score: 9.35 Seq: 264 291 Model: 1 34
			*CnqNPGtCvNtpmYtciCpeGYmyYtGrrC*
			C++ C + G+ + + + +C+C++G
			Y G +C
			CSL-QLVH-GRFREEEC--SCVCDIG---YGGAAQC
			291
T139pro	232		
T139pro	264		

FIG. 2C




FIG. 3

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

(i) APPLICANT: Holtzman, Douglas

(ii) TITLE OF THE INVENTION: NOVEL MOLECULES OF THE T139-RELATED PROTEIN FAMILY AND USES THEREOF

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Richardson P.C.  
(B) STREET: 225 Franklin Street  
(C) CITY: Boston  
(D) STATE: MA  
(E) COUNTRY: USA  
(F) ZIP: 02110-2804

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette  
(B) COMPUTER: IBM Compatible  
(C) OPERATING SYSTEM: Windows95  
(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE: 23-APR-1998

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:  
(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Meiklejohn, Ph.D., Anita L.  
(B) REGISTRATION NUMBER: 35,283  
(C) REFERENCE/DOCKET NUMBER: 09404/047001

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 617/542-5070  
(B) TELEFAX: 617/542-8906  
(C) TELEX: 200154

## (2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1856 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence  
(B) LOCATION: 95...1432

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GTCGACCCAC GCGTCCGGCT CCATCCAGCC TGAGAACAA GCCGGGTGGC TGAGCCAGGC 60  
TGTGCACGGA GTGCCCTGACG GGCCCAACAG ACCC ATG CTG CAT CCA GAG ACC TCC 115  
Met Leu His Pro Glu Thr Ser

CCT GGC CGG GGG CAT CTC CTG GCT GTG CTC CTG GCC CTC CTT GGC ACC Pro Gly Arg Gly His Leu Leu Ala Val Leu Leu Ala Leu Leu Gly Thr 10 15 20	163
GCC TGG GCA GAG GTG TGG CCA CCC CAG CTG CAG GAG CAG GCT CCG ATG Ala Trp Ala Glu Val Trp Pro Pro Gln Leu Gln Glu Gln Ala Pro Met 25 30 35	211
GCC GGA GCC CTG AAC AGG AAG GAG AGT TTC TTG CTC CTC TCC CTG CAC Ala Gly Ala Leu Asn Arg Lys Glu Ser Phe Leu Leu Ser Leu His 40 45 50 55	259
AAC CGC CTG CGC AGC TGG GTC CAG CCC CCT GCG GCT GAC ATG CGG AGG Asn Arg Leu Arg Ser Trp Val Gln Pro Pro Ala Ala Asp Met Arg Arg 60 65 70	307
CTG GAC TGG AGT GAC AGC CTG GCC CAA CTG GCT CAA GCC AGG GCA GCC Leu Asp Trp Ser Asp Ser Leu Ala Gln Leu Ala Gln Ala Arg Ala Ala 75 80 85	355
CTC TGT GGA ATC CCA ACC CCG AGC CTG GCG TCC GGC CTG TGG CGC ACC Leu Cys Gly Ile Pro Thr Pro Ser Leu Ala Ser Gly Leu Trp Arg Thr 90 95 100	403
CTG CAA GTG GGC TGG AAC ATG CAG CTG CTG CCC GCG GGC TTG GCG TCC Leu Gln Val Gly Trp Asn Met Gln Leu Leu Pro Ala Gly Leu Ala Ser 105 110 115	451
TTT GTT GAA GTG GTC AGC CTA TGG TTT GCA GAG GGG CAG CGG TAC AGC Phe Val Glu Val Val Ser Leu Trp Phe Ala Glu Gly Gln Arg Tyr Ser 120 125 130 135	499
CAC GCG GCA GGA GAG TGT GCT CGC AAC GCC ACC TGC ACC CAC TAC ACG His Ala Ala Gly Glu Cys Ala Arg Asn Ala Thr Cys Thr His Tyr Thr 140 145 150	547
CAG CTC GTG TGG GCC ACC TCA AGC CAG CTG GGC TGT GGG CGG CAC CTG Gln Leu Val Trp Ala Thr Ser Ser Gln Leu Gly Cys Gly Arg His Leu 155 160 165	595
TGC TCT GCA GGC CAG GCA GCG ATA GAA GCC TTT GTC TGT GCC TAC TCC Cys Ser Ala Gly Gln Ala Ala Ile Glu Ala Phe Val Cys Ala Tyr Ser 170 175 180	643
CCC GGA GGC AAC TGG GAG GTC AAC GGG AAG ACA ATC ATC CCC TAT AAG Pro Gly Gly Asn Trp Glu Val Asn Gly Lys Thr Ile Ile Pro Tyr Lys 185 190 195	691
AAG GGT GCC TGG TGT TCG CTC TGC ACA GCA AGT GTC TCA GGC TGC TTC Lys Gly Ala Trp Cys Ser Leu Cys Thr Ala Ser Val Ser Gly Cys Phe 200 205 210 215	739
AAA GCC TGG GAC CAT GCA GGG GGG CTC TGT GAG GTC CCC AGG AAT CCT Lys Ala Trp Asp His Ala Gly Gly Leu Cys Glu Val Pro Arg Asn Pro 220 225 230	787
TGT CGC ATG AGC TGC CAG AAC CAT GGA CGT CTC AAC ATC AGC ACC TGC Cys Arg Met Ser Cys Gln Asn His Gly Arg Leu Asn Ile Ser Thr Cys 235 240 245	835
CAC TGC CAC TGT CCC CCT GGC TAC ACG GGC AGA TAC TGC CAA GTG AGG His Cys His Cys Pro Pro Gly Tyr Thr Gly Arg Tyr Cys Gln Val Arg 250 255 260	883

TGC AGC CTG CAG TGT GTG CAC GGC CGG TTC CGG GAG GAG TGC TCG Cys Ser Leu Gln Cys Val His Gly Arg Phe Arg Glu Glu Glu Cys Ser 265 270 275	931
TGC GTC TGT GAC ATC GGC TAC GGG GGA GCC CAG TGT GCC ACC AAG GTG Cys Val Cys Asp Ile Gly Tyr Gly Ala Gin Cys Ala Thr Lys Val 280 285 290 295	979
CAT TTT CCC TTC CAC ACC TGT GAC CTG AGG ATC GAC GGA GAC TGC TTC His Phe Pro Phe His Thr Cys Asp Leu Arg Ile Asp Gly Asp Cys Phe 300 305 310	1027
ATG GTG TCT TCA GAG GCA GAC ACC TAT TAC AGA GCC AGG ATG AAA TGT Met Val Ser Ser Glu Ala Asp Thr Tyr Tyr Arg Ala Arg Met Lys Cys 315 320 325	1075
CAG AGG AAA GGC GGG GTG CTG GCC CAG ATC AAG AGC CAG AAA GTG CAG Gln Arg Lys Gly Gly Val Leu Ala Gln Ile Lys Ser Gln Lys Val Gln 330 335 340	1123
GAC ATC CTC GCC TTC TAT CTG GGC CGC CTG GAG ACC ACC AAC GAG GTG Asp Ile Leu Ala Phe Tyr Leu Gly Arg Leu Glu Thr Thr Asn Glu Val 345 350 355	1171
ATT GAC AGT GAC TTC GAG ACC AGG AAC TTC TGG ATC GGG CTC ACC TAC Ile Asp Ser Asp Phe Glu Thr Arg Asn Phe Trp Ile Gly Leu Thr Tyr 360 365 370 375	1219
AAG ACC GCC AAG GAC TCC TTC CGC TGG GCC ACA GGG GAG CAC CAG GCC Lys Thr Ala Lys Asp Ser Phe Arg Trp Ala Thr Gly Glu His Gln Ala 380 385 390	1267
TTC ACC AGT TTT GCC TTT GGG CAG CCT GAC AAC CAC GGG TTT GGC AAC Phe Thr Ser Phe Ala Phe Gly Gln Pro Asp Asn His Gly Phe Gly Asn 395 400 405	1315
TGC GTG GAG CTG CAG GCT TCA GCT GCC TTC AAC TGG AAC AAC CAG CGC Cys Val Glu Leu Gln Ala Ser Ala Ala Phe Asn Trp Asn Asn Gln Arg 410 415 420	1363
TGC AAA ACC CGA AAC CGT TAC ATC TGC CAG TTT GCC CAG GAG CAC ATC Cys Lys Thr Arg Asn Arg Tyr Ile Cys Gln Phe Ala Gln Glu His Ile 425 430 435	1411
TCC CGG TGG GGC CCA GGG TCC TGAGGCCTGA CCACATGGCT CCCTCGCCTG CCCT Ser Arg Trp Gly Pro Gly Ser 440 445	1466
GGGAGCACCG GCTCTGCTTA CCTGTCCGCC CACCTGCTG GAACAAGGGC CAGGTTAAGA CCACATGCCT CATGTCCAAA GAGGTCTCAG ACCTTGACCA ATGCCAGAG TTGGGCAGAG AGAGGCAGGG AGGCCAGTGA GGGCCAGGG A GTGAGTGTGA GAAGAAGCTG GGGCCCTTCG CCTGCTTTG ATTGGGAAGA TGGGCTTCAA TTAGATGGCA AAGGAGAGGA CACCGCCAGT GGTCCAAAAA GGCTGCTCTC TTCCACCTGG CCCAGACCT GTGGGGCAGC GGAGCTTCCC TGTGGCATGA ACCCCACAGG GTATTAATT ATGAATCAGC TGAAAAAAAAA AAAAAAAA AAAAAAAAAA AAAAAAAA GGGCGGCCGC	1526 1586 1646 1706 1766 1826 1856

## (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 446 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Leu His Pro Glu Thr Ser Pro Gly Arg Gly His Leu Leu Ala Val  
1 5 10 15  
Leu Leu Ala Leu Leu Gly Thr Ala Trp Ala Glu Val Trp Pro Pro Gln  
20 25 30  
Leu Gln Glu Gln Ala Pro Met Ala Gly Ala Leu Asn Arg Lys Glu Ser  
35 40 45  
Phe Leu Leu Leu Ser Leu His Asn Arg Leu Arg Ser Trp Val Gln Pro  
50 55 60  
Pro Ala Ala Asp Met Arg Arg Leu Asp Trp Ser Asp Ser Leu Ala Gln  
65 70 75 80  
Leu Ala Gln Ala Arg Ala Ala Leu Cys Gly Ile Pro Thr Pro Ser Leu  
85 90 95  
Ala Ser Gly Leu Trp Arg Thr Leu Gln Val Gly Trp Asn Met Gln Leu  
100 105 110  
Leu Pro Ala Gly Leu Ala Ser Phe Val Glu Val Val Ser Leu Trp Phe  
115 120 125  
Ala Glu Gly Gln Arg Tyr Ser His Ala Ala Gly Glu Cys Ala Arg Asn  
130 135 140  
Ala Thr Cys Thr His Tyr Thr Gln Leu Val Trp Ala Thr Ser Ser Gln  
145 150 155 160  
Leu Gly Cys Gly Arg His Leu Cys Ser Ala Gly Gln Ala Ala Ile Glu  
165 170 175  
Ala Phe Val Cys Ala Tyr Ser Pro Gly Gly Asn Trp Glu Val Asn Gly  
180 185 190  
Lys Thr Ile Ile Pro Tyr Lys Lys Gly Ala Trp Cys Ser Leu Cys Thr  
195 200 205  
Ala Ser Val Ser Gly Cys Phe Lys Ala Trp Asp His Ala Gly Gly Leu  
210 215 220  
Cys Glu Val Pro Arg Asn Pro Cys Arg Met Ser Cys Gln Asn His Gly  
225 230 235 240  
Arg Leu Asn Ile Ser Thr Cys His Cys His Cys Pro Pro Gly Tyr Thr  
245 250 255  
Gly Arg Tyr Cys Gln Val Arg Cys Ser Leu Gln Cys Val His Gly Arg  
260 265 270  
Phe Arg Glu Glu Cys Ser Cys Val Cys Asp Ile Gly Tyr Gly Gly  
275 280 285  
Ala Gln Cys Ala Thr Lys Val His Phe Pro Phe His Thr Cys Asp Leu  
290 295 300  
Arg Ile Asp Gly Asp Cys Phe Met Val Ser Ser Glu Ala Asp Thr Tyr  
305 310 315 320  
Tyr Arg Ala Arg Met Lys Cys Gln Arg Lys Gly Gly Val Leu Ala Gln  
325 330 335  
Ile Lys Ser Gln Lys Val Gln Asp Ile Leu Ala Phe Tyr Leu Gly Arg  
340 345 350  
Leu Glu Thr Thr Asn Glu Val Ile Asp Ser Asp Phe Glu Thr Arg Asn  
355 360 365  
Phe Trp Ile Gly Leu Thr Tyr Lys Thr Ala Lys Asp Ser Phe Arg Trp  
370 375 380  
Ala Thr Gly Glu His Gln Ala Phe Thr Ser Phe Ala Phe Gly Gln Pro  
385 390 395 400  
Asp Asn His Gly Phe Gly Asn Cys Val Glu Leu Gln Ala Ser Ala Ala  
405 410 415  
Phe Asn Trp Asn Asn Gln Arg Cys Lys Thr Arg Asn Arg Tyr Ile Cys  
420 425 430  
Gln Phe Ala Gln Glu His Ile Ser Arg Trp Gly Pro Gly Ser  
435 440 445

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1338 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGCTGCATC	CAGAGACCTC	CCCTGGCCGG	GGGCATCTCC	TGGCTGTGCT	CCTGGCCCTC	60
CTTGGCACCG	CCTGGCAGA	GGTGTGGCA	CCCCAGCTGC	AGGAGCAGGC	TCCGATGGCC	120
GGAGCCCTGA	ACAGGAAGGA	GAGTTTCTTG	CTCCCTCTCC	TGCACAACCG	CCTGCGCAGC	180
TGGGTCCAGC	CCCCCTGCGG	TGACATGCGG	AGGCTGGACT	GGAGTGACAG	CCTGGCCCAA	240
CTGGCTCAAG	CCAGGGCAGC	CCTCTGTGGA	ATCCCAACCC	CGAGCCTGGC	GTCCGGCCTG	300
TGGCGCACCC	TGCAAGTGGG	CTGGAACATG	CAGCTGCTGC	CCGGGGCTT	GGCGTCCITT	360
GTTGAAGTGG	TCAGCTATG	GTGGCAGAG	GGGCAGCGGT	ACAGCCACGC	GGCAGGAGAG	420
TGTGCTCGCA	ACGCCACCTG	CACCCACTCG	ACCGCAGCTCG	TGTGGGCAAC	CTCAAGCCAG	480
CTGGGCTGTG	GGCGGCACCT	GTGCTCTGCA	GGCCAGGCAG	CGATAGAACG	CTTTGTCTGT	540
GCCTACTCCC	CCGGAGGCAA	CTGGGGAGGTC	AACGGGAAGA	CAATCATCCC	CTATAAGAAG	600
GGTGCTGTT	GTTCGCTCTG	CACAGCCAGT	GTCTCAGGCT	GCTTCAAAGC	CTGGGACCAT	660
GCAGGGGGC	TCTGTGAGGT	CCCCAGGAAT	CCTTGTGCGA	TGAGCTGCCA	GAACCATGGA	720
CGTCTCAACA	TCAGCACCTG	CCACTGCCAC	TGTCCCCCTG	GCTACACGGG	CAGATACTGC	780
CAAGTGAGGT	GCAGCCTGCA	GTGTTGTCAC	GGCCGGITTC	GGGAGGAGGA	GTGCTCGTGC	840
GTCTGTGACA	TCGGCTACGG	GGGAGGCCCAG	TGTGCCACCA	AGGTGCATTT	TCCCTTCCAC	900
ACCTGTGACC	TGAGGATCGA	CGGAGACTGC	TTCATGGTGT	CTTCAGAGGC	AGACACCTAT	960
TACAGAGCCA	GGATGAAATG	TCAGAGGAAA	GGCGGGGTGC	TGGCCCAGAT	CAAGAGCCAG	1020
AAAGTGCAGG	ACATCCTCGC	CTTCTATCTG	GGCCGCCCTGG	AGACCACCAA	CGAGGTGATT	1080
GACAGTGACT	TCGAGACCAG	GAACTTCTGG	ATCGGGCTCA	CCTACAAGAC	CGCCAAGGAC	1140
TCCCTTCCGCT	GGGCCACAGG	GGAGCACCAG	GCCTTCACCA	GTTTTGCTT	TGGGCAGCCT	1200
GACAACCACG	GGTTTGGCAA	CTGCGTGGAG	CTGCAGGCTT	CAGCTGCCCTT	CAACTGGAAC	1260
AACCAAGGCT	GCAAAACCCG	AAACCGTTAC	ATCTGCCAGT	TTGCCAGGA	GCACATCTCC	1320
CGGTGGGGCC	CAGGGTCC					1338

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 420 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu	Val	Trp	Pro	Pro	Gln	Leu	Gln	Glu	Gln	Ala	Pro	Met	Ala	Gly	Ala
1					5			10		15					
Leu	Asn	Arg	Lys	Glu	Ser	Phe	Leu	Leu	Leu	Ser	Leu	His	Asn	Arg	Leu
							20		25		30				
Arg	Ser	Trp	Val	Gln	Pro	Pro	Ala	Ala	Asp	Met	Arg	Arg	Leu	Asp	Trp
							35		40		45				
Ser	Asp	Ser	Leu	Ala	Gln	Leu	Ala	Gln	Ala	Arg	Ala	Ala	Leu	Cys	Gly
							50		55		60				
Ile	Pro	Thr	Pro	Ser	Leu	Ala	Ser	Gly	Leu	Trp	Arg	Thr	Leu	Gln	Val
							65		70		75		80		
Gly	Trp	Asn	Met	Gln	Leu	Leu	Pro	Ala	Gly	Leu	Ala	Ser	Phe	Val	Glu
							85		90		95				
Val	Val	Ser	Leu	Trp	Phe	Ala	Glu	Gly	Gln	Arg	Tyr	Ser	His	Ala	Ala
							100		105		110				
Gly	Glu	Cys	Ala	Arg	Asn	Ala	Thr	Cys	Thr	His	Tyr	Thr	Gln	Leu	Val
							115		120		125				

Trp Ala Thr Ser Ser Gln Leu Gly Cys Gly Arg His Leu Cys Ser Ala  
130 135 140  
Gly Gln Ala Ala Ile Glu Ala Phe Val Cys Ala Tyr Ser Pro Gly Gly  
145 150 155 160  
Asn Trp Glu Val Asn Gly Lys Thr Ile Ile Pro Tyr Lys Lys Gly Ala  
165 170 175  
Trp Cys Ser Leu Cys Thr Ala Ser Val Ser Gly Cys Phe Lys Ala Trp  
180 185 190  
Asp His Ala Gly Gly Leu Cys Glu Val Pro Arg Asn Pro Cys Arg Met  
195 200 205  
Ser Cys Gln Asn His Gly Arg Leu Asn Ile Ser Thr Cys His Cys His  
210 215 220  
Cys Pro Pro Gly Tyr Thr Gly Arg Tyr Cys Gln Val Arg Cys Ser Leu  
225 230 235 240  
Gln Cys Val His Gly Arg Phe Arg Glu Glu Glu Cys Ser Cys Val Cys  
245 250 255  
Asp Ile Gly Tyr Gly Gly Ala Gln Cys Ala Thr Lys Val His Phe Pro  
260 265 270  
Phe His Thr Cys Asp Leu Arg Ile Asp Gly Asp Cys Phe Met Val Ser  
275 280 285  
Ser Glu Ala Asp Thr Tyr Tyr Arg Ala Arg Met Lys Cys Gln Arg Lys  
290 295 300  
Gly Gly Val Leu Ala Gln Ile Lys Ser Gln Lys Val Gln Asp Ile Leu  
305 310 315 320  
Ala Phe Tyr Leu Gly Arg Leu Glu Thr Thr Asn Glu Val Ile Asp Ser  
325 330 335  
Asp Phe Glu Thr Arg Asn Phe Trp Ile Gly Leu Thr Tyr Lys Thr Ala  
340 345 350  
Lys Asp Ser Phe Arg Trp Ala Thr Gly Glu His Gln Ala Phe Thr Ser  
355 360 365  
Phe Ala Phe Gly Gln Pro Asp Asn His Gly Phe Gly Asn Cys Val Glu  
370 375 380  
Leu Gln Ala Ser Ala Ala Phe Asn Trp Asn Asn Gln Arg Cys Lys Thr  
385 390 395 400  
Arg Asn Arg Tyr Ile Cys Gln Phe Ala Gln Glu His Ile Ser Arg Trp  
405 410 415  
Gly Pro Gly Ser  
420